Chronic Lymphocytic Leukemia | Specialty

Combination Therapies in CLL

January 12th 2018

Additional Therapies for R/R CLL

January 12th 2018

Therapeutic Approaches for R/R CLL

January 12th 2018

Maintenance and Frontline Therapy in CLL

January 12th 2018

Managing Patients With CLL

January 12th 2018

Safety and Efficacy of CLL Treatments

January 12th 2018

Therapeutic Approaches for CLL

January 12th 2018

Deciding on CLL Therapy and When to Treat

January 12th 2018

CLL: The Risk of Richter's Transformation

January 12th 2018

The Risk-Stratifying Factors in CLL

January 12th 2018

Combination Therapies Poised to Improve CLL Treatment Landscape

January 8th 2018

Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.

Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

January 6th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor

January 4th 2018

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).

Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL

January 3rd 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

December 22nd 2017

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Dr. Logan Discusses Treatment Options in CLL

December 19th 2017

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia.

Dr. Davids on Ibrutinib Plus FCR in Younger Patients With CLL

December 16th 2017

Matthew S. Davids, MD, MMSc, Associate Director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib plus FCR in younger patients with CLL.

Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy

December 14th 2017

Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.

Combinations Have Potential to Shift CLL Treatment Paradigm

December 13th 2017

Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.

Dr. Flinn on Venetoclax and Obinutuzumab in CLL

December 12th 2017

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.